These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22509073)

  • 41. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
    Dhayat S; Mardin WA; Mees ST; Haier J
    Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
    PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?
    Jiang JH; Liu C; Cheng H; Lu Y; Qin Y; Xu YF; Xu J; Long J; Liu L; Ni QX; Yu XJ
    Biochim Biophys Acta; 2015 Jan; 1855(1):43-9. PubMed ID: 25432020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells.
    Rencuzogulları O; Yerlikaya PO; Gürkan AÇ; Arısan ED; Telci D
    J Cell Biochem; 2020 Jan; 121(1):508-523. PubMed ID: 31264276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in understanding the molecular mechanism of pancreatic cancer metastasis.
    Du YX; Liu ZW; You L; Wu WM; Zhao YP
    Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):361-70. PubMed ID: 27498575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
    Mohelnikova-Duchonova B; Melichar B
    Pancreatology; 2013; 13(6):558-63. PubMed ID: 24280569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/β-Catenin Signal via ST7L.
    Zhan T; Chen X; Tian X; Han Z; Liu M; Zou Y; Huang S; Chen A; Cheng X; Deng J; Tan J; Huang X
    Technol Cancer Res Treat; 2020; 19():1533033820945801. PubMed ID: 32924881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
    Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA
    Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
    Matsuoka T; Yashiro M
    World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
    Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
    Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.
    Kyuno D; Yamaguchi H; Ito T; Kono T; Kimura Y; Imamura M; Konno T; Hirata K; Sawada N; Kojima T
    World J Gastroenterol; 2014 Aug; 20(31):10813-24. PubMed ID: 25152584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
    Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The low chamber pancreatic cancer cells had stem-like characteristics in modified transwell system: is it a novel method to identify and enrich cancer stem-like cells?
    Wang D; Zhu H; Liu Y; Liu Q; Xie X; Zhou Y; Zhang L; Zhu Y; Zhang Z; Su Z
    Biomed Res Int; 2014; 2014():760303. PubMed ID: 24689055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma.
    Yee NS; Kazi AA; Yee RK
    Curr Clin Pharmacol; 2015; 10(4):256-66. PubMed ID: 26548903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
    McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
    World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
    Chung JH; Rho JK; Xu X; Lee JS; Yoon HI; Lee CT; Choi YJ; Kim HR; Kim CH; Lee JC
    Lung Cancer; 2011 Aug; 73(2):176-82. PubMed ID: 21168239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.